On Wednesday shares of CSX Corp. (NYSE:CSX) closed at $35.65. Company’s sales growth for last 5 years was 7.00% and EPS growth for next 5 years is recorded as 9.87%. U.S. regulators took on the powerful rail industry on Friday, announcing plans to require expensive, high-tech braking technology the railways insist is unproven and unreliable. CSX Corp (NYSE:CSX) said it was “deeply troubled” by the brake requirement, and that ECP brakes have not been proven in regular service.
Arrowhead Research Corp. (NASDAQ:ARWR) in last trading activity fell -0.87% to close at $6.87. Company weekly performance is -2.28% while its quarterly performance stands at 10.63%. Arrowhead Research Corp. (NASDAQ:ARWR) is -60.56% away from its 52 week high. Arrowhead Research Corporation (NASDAQ: ARWR) announced that it completed dosing healthy volunteers and will begin dosing patients in an on-going phase 1 study of ARC-AAT, the Company’s clinical candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency (AATD).
On last trading day Genetic Technologies Limited (NASDAQ:GENE) fell -1.79% to close at $4.38. Its volatility for the week is 8.71% while volatility for the month is 7.60%. GENE’s sales growth for past 5 years was -16.80% and its EPS growth for past 5 years was 3.40%. Genetic Technologies Limited (NASDAQ:GENE) monthly performance is -0.45%. On 4 May, Genetic Technologies Limited (NASDAQ: GENE) reported that the second of two Nasdaq deficiencies, previously notified to the market, has been successfully remediated.
Gaiam Inc. (NASDAQ:GAIA) has 1.10% insider ownership while its institutional ownership stands at 76.10%. In last trading activity company’s stock closed at $6.73. Gaiam Inc. (NASDAQ:GAIA) carries a Zacks Rank #2 (Buy).
On last trading day Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) increased 3.48% to close at $60.37. Its volatility for the week is 6.18% while volatility for the month is 4.59%. ISIS’s sales growth for past 5 years was 12.00% and its EPS growth for past 5 years was -1.30%. Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) monthly performance is -1.81%. Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) reported pro forma operating income of $4.0 million for the three months ended March 31, 2015 compared to a pro forma net operating loss of $22.6 million for the same period in 2014. Isis’ significantly improved financial results were due to higher revenue from milestone payments earned from its partners compared to the same quarter last year.